We’re excited to share that Biocytogen will be attending the 16th Annual World ADC, taking place November 3 – 6 in San Diego, CA! Join us for four days of insightful presentations, roundtable discussions, and networking opportunities, covering a broad spectrum of topics from early discovery to clinical development. Meet us at booth #45 to connect with the Biocytogen team and learn more about our drug development progress and advancements in preclinical research. We look forward to seeing you there.
What is the 16th Annual World ADC?
As the leading and longest-running event dedicated to antibody-drug conjugates, the 16th World ADC San Diego focuses on highlighting groundbreaking advancements that are moving ADCs into earlier stages of cancer treatment. The 2025 program will showcase innovation across ADC’s developments, aiming to ensure that future antibody drug conjugates will provide further benefits to oncology patients. With over 1,200 attendees each year, the event offers a chance to engage in scientific poster sessions, connect through exhibition networking, and share the latest breakthroughs aimed at advancing cancer treatment.
Event Overview
Date: November 3rd- 6th, 2025
Venue: Town & Country San Diego, 500 Hotel Circle, North San Diego, CA, 92108
Event Schedule
For more information, please refer to ADC Full Event Guide.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We can’t wait to see you in San Diego!
